Literature DB >> 17124430

Elevated soluble ADAM8 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia.

Osamu Matsuno1, Eishi Miyazaki, Shinichi Nureki, Takuya Ueno, Masaru Ando, Kazunobu Ito, Toshihide Kumamoto, Yasunori Higuchi.   

Abstract

BACKGROUND: ADAM (a disintegrin and metalloprotease) family members, characterized by a metalloprotease and a disintegrin domain, are membrane-anchored glycoproteins involved in proteolysis and cell adhesion. ADAM8 might have an important role in allergic inflammation. It can cleave a variety of substrates and is a sheddase for VCAM-1 and CD23, the low-affinity IgE receptors.
METHODS: To evaluate the contribution of ADAM8 to the pathogenesis of eosinophilic pneumonia (EP), we measured the concentrations of soluble ADAM8 (sADAM8) and its substrates, soluble VCAM-1 (sVCAM-1) and soluble CD23 (sCD23), in bronchoalveolar lavage fluid from patients with smoking-induced acute eosinophilic pneumonia (AEP), chronic idiopathic eosinophilic pneumonia (CEP), and drug-induced eosinophilic pneumonia (drug-EP).
RESULTS: The sADAM8 and sVCAM-1 concentrations were increased in AEP and CEP. The sCD23 concentration was elevated in AEP. In AEP, but not CEP, the sADAM8 concentration significantly correlated with those of both sVCAM and sCD23.
CONCLUSION: The pathogenesis of AEP, CEP, and drug-EP was distinct with regard to ADAM8. Our results are the first to associate ADAM8 with eosinophilic responses and lung inflammation in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17124430     DOI: 10.1159/000097359

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  8 in total

1.  Expression of ADAMs ("a disintegrin and metalloprotease") in the human lung.

Authors:  Antoon Dijkstra; Dirkje S Postma; Jacobien A Noordhoek; Monique E Lodewijk; Henk F Kauffman; Nick H T ten Hacken; Wim Timens
Journal:  Virchows Arch       Date:  2009-03-03       Impact factor: 4.064

Review 2.  Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants.

Authors:  Joan M Cook-Mills; Michelle E Marchese; Hiam Abdala-Valencia
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

Review 3.  Eosinophilic pneumonias.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 4.  ADAM8: a new therapeutic target for asthma.

Authors:  Martin D Knolle; Caroline A Owen
Journal:  Expert Opin Ther Targets       Date:  2009-05       Impact factor: 6.902

5.  Upregulation of ADAM8 in the airways of mice with allergic bronchial asthma.

Authors:  Yoshihiko Chiba; Satoshi Onoda; Yoshiyuki Hattori; Yoshie Maitani; Hiroyasu Sakai; Miwa Misawa
Journal:  Lung       Date:  2009-04-17       Impact factor: 2.584

6.  [Idiopathic chronic eosinophilic pneumonia - a diagnostic challenge].

Authors:  Ertunc Altiok; Rolf Kemper; Joachim Kindler
Journal:  Med Klin (Munich)       Date:  2009-07-18

Review 7.  New insights of P2X7 receptor signaling pathway in alveolar functions.

Authors:  Amarjit Mishra
Journal:  J Biomed Sci       Date:  2013-05-01       Impact factor: 8.410

8.  A novel peptide ADAM8 inhibitor attenuates bronchial hyperresponsiveness and Th2 cytokine mediated inflammation of murine asthmatic models.

Authors:  Jun Chen; Linhong Deng; Daniela Dreymüller; Xuemei Jiang; Jiaoyue Long; Yiyuan Duan; Yue Wang; Mingzhi Luo; Feng Lin; Lizhen Mao; Bernd Müller; Garrit Koller; Jörg W Bartsch
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.